While FDA action dates may have come and gone on some biosimilar applications, known as 351(k)s, it would be wrong to make an assumption regulators had issued a complete response letter (CRL) due to the lack of biosimilarity, warned Leah Christl, associate director for therapeutic biologics.
"As a general matter, for any application, there's a number of things that could create a bump in the road,"...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?